Zosano Pharma (NASDAQ:ZSAN) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of Zosano Pharma (NASDAQ:ZSANGet Rating) in a report published on Monday. The firm issued a sell rating on the biotechnology company’s stock.

Separately, BTIG Research downgraded shares of Zosano Pharma from a buy rating to a neutral rating in a report on Wednesday, February 23rd.

Shares of NASDAQ:ZSAN opened at $0.12 on Monday. The company has a market capitalization of $20.32 million, a price-to-earnings ratio of -0.45 and a beta of 2.98. The firm’s 50 day simple moving average is $0.22 and its 200 day simple moving average is $0.46. Zosano Pharma has a fifty-two week low of $0.11 and a fifty-two week high of $1.19.

Zosano Pharma (NASDAQ:ZSANGet Rating) last announced its quarterly earnings results on Thursday, March 17th. The biotechnology company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). Zosano Pharma had a negative net margin of 3,812.10% and a negative return on equity of 80.12%. On average, equities analysts anticipate that Zosano Pharma will post -0.22 earnings per share for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Morgan Stanley raised its holdings in shares of Zosano Pharma by 954.9% in the first quarter. Morgan Stanley now owns 45,879 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 41,530 shares during the last quarter. LPL Financial LLC grew its stake in shares of Zosano Pharma by 95.7% in the third quarter. LPL Financial LLC now owns 58,700 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 28,700 shares in the last quarter. Millennium Management LLC bought a new position in shares of Zosano Pharma in the second quarter valued at $65,000. Citadel Advisors LLC grew its stake in shares of Zosano Pharma by 263.9% in the third quarter. Citadel Advisors LLC now owns 146,166 shares of the biotechnology company’s stock valued at $105,000 after buying an additional 105,999 shares in the last quarter. Finally, Barclays PLC grew its stake in shares of Zosano Pharma by 50.0% in the third quarter. Barclays PLC now owns 300,000 shares of the biotechnology company’s stock valued at $216,000 after buying an additional 100,000 shares in the last quarter. Institutional investors own 10.57% of the company’s stock.

Zosano Pharma Company Profile (Get Rating)

Zosano Pharma Corp. is a clinical stage biopharmaceutical company, which engages in the development of human pharmaceutical products. The firm focuses on providing rapid systemic administration of therapeutics to patients using proprietary intracutaneous microneedle system. It offers Qtrypta, a formulation of zolmitriptan delivered utilizing the intracutaneous microneedle system.

Read More

Receive News & Ratings for Zosano Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zosano Pharma and related companies with MarketBeat.com's FREE daily email newsletter.